SBI Securities Co. Ltd. Purchases New Shares in Moderna, Inc. (NASDAQ:MRNA)

SBI Securities Co. Ltd. acquired a new position in Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, Holdings Channel reports. The fund acquired 18,059 shares of the company’s stock, valued at approximately $751,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MRNA. State Street Corp grew its holdings in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP grew its stake in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the period. Two Sigma Advisers LP bought a new position in Moderna in the 3rd quarter valued at $23,825,000. Douglas Lane & Associates LLC raised its stake in shares of Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock worth $32,175,000 after purchasing an additional 298,715 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Moderna by 6.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after buying an additional 178,939 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Wolfe Research assumed coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 price target (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Argus lowered Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $60.63.

Moderna Price Performance

Shares of MRNA opened at $30.27 on Tuesday. The firm has a market capitalization of $11.68 billion, a P/E ratio of -3.26 and a beta of 1.59. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47. The business has a fifty day moving average of $37.12 and a 200 day moving average of $50.28.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.